The 340B markup program is a goldmine for big nonprofit 340B hospitals.
No rules. No transparency. Patients pay the price.
It’s time for Washington to fix 340B.
NEW: IQVIA released a new study exposing a patient medicine denial crisis.
🚨 7️⃣0️⃣% of patients seeking branded medicines through commercial insurance were initially denied coverage, forcing patients to give up on their medicines or navigate a maze of appeals. Delays like that can have serious consequences for health outcomes.
America’s leadership in medicine development matters.
It matters because our leadership has delivered lifesaving breakthroughs and fueled economic opportunity nationwide.
But for the first time in decades, America’s spot as a global leader is on the line. To sustain our position of leadership, we need smart policies that will deliver more cures, more jobs and lower costs for Americans.
Learn more at the link in our bio.
NEW ANALYSIS: Patients in other countries wait longer and have fewer options for innovative medicines.
Read the report for to see how other countries undervalue innovation and block access to new medicines— and what’s at stake if U.S. policymakers import foreign price controls that jeopardize patient access ➡️ Learn more at the link in our bio.
A program created to help vulnerable patients is facing growing questions about transparency, accountability and where 340B profits are actually going.
This @foxbusiness segment highlights why policymakers and patients alike are taking a closer look at the program.
Every generic and biosimilar exists because of a brand medicine. 90% of prescriptions filled in the U.S. are low-cost generics – and medicines are one of the only areas in health care where prices go down over time.
At @CNBC ’s #InvestInAmericaForum, our CEO, Stephen Ubl highlighted how this dynamic creates room for new innovation while maintaining affordability for patients. #cnbcevents
Vaccines are built with decades of knowledge, and every vaccine is carefully designed for safety and protection.
America has addressed the threat of diseases like smallpox, polio, and hepatitis B, but that progress isn’t permanent. When vaccination rates fall, these deadly diseases return.
Maintaining U.S. leadership in life sciences requires action.
Our CEO, Stephen J. Ubl, joined @CNBC to talk about what action is needed:
🧪 More efficient clinical trials
🚧 Fewer barriers from PBMs and insurers
🧬 Policies that support investment in innovation
The decisions we make today will determine whether America continues to lead. #InvestInAmericaForum #cnbcevents
Nearly 1 in 4 Americans—including 1 in 5 children—live with a mental health condition, yet only about half of adults seek treatment. That gap matters—but so does what we know: treatment works.
Medications, often used alongside behavioral therapy, can significantly improve quality of life, reduce relapses, and help prevent hospitalizations for those with a mental health condition.
As with physical health, when people become sick, prescription medicines can be an important part of care—one of several tools available to patients, providers, and caregivers in building a personalized treatment plan. Reducing stigma and ensuring access to patient-centered care are essential steps toward helping more people get the support they need and deserve.
Learn more at PhRMA.org/MentalHealth
The Washington Post Editorial Board is the latest to join the chorus of voices calling for federal reform of the 340B Program.
The Board warns that unchecked growth has turned 340B into a profit center for large hospital systems, driving up costs for everyone else.
A few things to know:
1️⃣ 340B does not operate as a targeted safety net program.
2️⃣ Hospitals can pocket drug discounts without helping patients.
3️⃣ The program is driving higher costs for patients, employers and taxpayers.
4️⃣ Transparency and accountability are sorely lacking.
America’s biopharmaceutical leadership fuels more than just medicine breakthroughs.
The biopharmaceutical industry fuels jobs, investment and economic growth in every state.
